Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
| 대상 질환 | KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7 |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | National Cancer Institute (NCI) |
| 상태 | 진행 중(모집 완료) |
| 참여자 수 | 60 명 |
| 중재(약물) | Docetaxel, Laboratory Biomarker Analysis, Trametinib |
| 시작일 | 2016년 7월 18일 |
| 완료일 | 2019년 5월 15일 |
| 결과 공개일 | 2021년 2월 2일 |
요약
This phase II trial studies how well trametinib and docetaxel work in treating patients with stage IV KRAS mutation positive non-small cell lung cancer or cancer that has come back. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trametinib with docetaxel may work better in treating non-small cell lung cancer.
Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in All KRAS Mutant Participants
| Treatment (Trametinib, Docetaxel) | 0.33 proportion of participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer — M.D. Anderson Cancer Center
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients W — National Cancer Institute (NCI)
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therap — National Cancer Institute (NCI)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)